HUTCHMED (HCM) Projected to Release Earnings on Thursday

HUTCHMED (NASDAQ:HCM) is projected to post its H1 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to post earnings of $0.1450 per share and revenue of $304.1560 million for the quarter. Interested persons may review the information on the company’s upcoming H1 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 8:00 AM ET.

HUTCHMED Stock Performance

Shares of NASDAQ:HCM opened at $11.20 on Wednesday. The business has a 50 day simple moving average of $11.05 and a two-hundred day simple moving average of $13.28. HUTCHMED has a 1 year low of $9.77 and a 1 year high of $19.50. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.83 and a current ratio of 4.96.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of HCM. Ameriprise Financial Inc. raised its position in HUTCHMED by 4.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock valued at $234,000 after purchasing an additional 698 shares in the last quarter. Bank of America Corp DE increased its stake in shares of HUTCHMED by 17.3% during the second quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock valued at $310,000 after buying an additional 3,035 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of HUTCHMED by 34.2% during the third quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock valued at $342,000 after buying an additional 5,538 shares during the period. BNP Paribas Financial Markets increased its stake in shares of HUTCHMED by 19.7% during the second quarter. BNP Paribas Financial Markets now owns 25,046 shares of the company’s stock valued at $377,000 after buying an additional 4,116 shares during the period. Finally, Goldman Sachs Group Inc. raised its holdings in shares of HUTCHMED by 8.5% in the first quarter. Goldman Sachs Group Inc. now owns 93,919 shares of the company’s stock valued at $1,413,000 after acquiring an additional 7,342 shares in the last quarter. 8.82% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on HCM shares. Bank of America dropped their price objective on HUTCHMED from $20.00 to $17.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. Weiss Ratings raised shares of HUTCHMED from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, July 17th. Morgan Stanley set a $13.60 price target on shares of HUTCHMED in a report on Thursday, May 28th. Finally, The Goldman Sachs Group reduced their price target on shares of HUTCHMED from $16.00 to $14.00 and set a “neutral” rating on the stock in a research note on Thursday, July 23rd. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, HUTCHMED presently has a consensus rating of “Hold” and a consensus target price of $14.87.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.